|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 579 DKK | +1.40% |
|
-2.69% | +24.84% |
| Apr. 22 | U.S. Futures, European Stocks Rise | DJ |
| Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
NKT A/S revised earnings guidance for the year 2023. Based on the financial performance so far in 2023, the financial outlook for the full-year is updated. Revenues (std.
metal prices) are expected to be approx. EUR 1.85-1.9 billion (previously approx. 1.8-1.9 billion).
| 1st Jan change | Capi. | |
|---|---|---|
| +24.84% | 4.45B | |
| +4.53% | 149B | |
| +34.66% | 130B | |
| +19.57% | 130B | |
| +12.90% | 62.82B | |
| +7.65% | 41.04B | |
| +94.65% | 35B | |
| +6.26% | 32.1B | |
| -9.78% | 32.1B | |
| +3.97% | 27.31B |
NKT A/S 
